Stock Track | Moderna Soars 6.06% in Pre-Market on Positive Cancer Vaccine Trial Results and Analyst Upgrade

Stock Track01-22 22:54

Moderna, Inc. (MRNA) saw its stock price soar 6.06% during pre-market trading on Thursday, continuing a strong rally from the previous session.

The surge is driven by positive five-year data from a Phase 2b clinical trial for Moderna's experimental skin cancer vaccine, developed in collaboration with Merck & Co. The data showed that adding Moderna's intismeran autogene to Merck's KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits observed over the five-year period.

Additionally, Bernstein raised its price target on Moderna to $35 from $25, reflecting increased confidence in the company's growth trajectory. This combination of promising clinical results and analyst optimism has fueled investor buying interest in the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162010567?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162010567","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars 6.06% in Pre-Market on Positive Cancer Vaccine Trial Results and Analyst Upgrade","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) saw its stock price soar 6.06% during pre-market trading on Thursday, continuing a strong rally from the previous session.</p><p>The surge is driven by positive five-year data from a Phase 2b clinical trial for Moderna's experimental skin cancer vaccine, developed in collaboration with Merck & Co. The data showed that adding Moderna's intismeran autogene to Merck's KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits observed over the five-year period.</p><p>Additionally, Bernstein raised its price target on Moderna to $35 from $25, reflecting increased confidence in the company's growth trajectory. This combination of promising clinical results and analyst optimism has fueled investor buying interest in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 6.06% in Pre-Market on Positive Cancer Vaccine Trial Results and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 6.06% in Pre-Market on Positive Cancer Vaccine Trial Results and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-22 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) saw its stock price soar 6.06% during pre-market trading on Thursday, continuing a strong rally from the previous session.</p><p>The surge is driven by positive five-year data from a Phase 2b clinical trial for Moderna's experimental skin cancer vaccine, developed in collaboration with Merck & Co. The data showed that adding Moderna's intismeran autogene to Merck's KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits observed over the five-year period.</p><p>Additionally, Bernstein raised its price target on Moderna to $35 from $25, reflecting increased confidence in the company's growth trajectory. This combination of promising clinical results and analyst optimism has fueled investor buying interest in the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1162010567","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162010567","pubTimestamp":1769093691,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) saw its stock price soar 6.06% during pre-market trading on Thursday, continuing a strong rally from the previous session.The surge is driven by positive five-year data from a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘前大涨6.06%因癌症疫苗试验结果积极及分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) saw its stock price soar 6.06% during pre-market trading on Thursday, continuing a strong rally from the previous session.The surge is driven by positive five-year data from a Phase 2b clinical trial for Moderna's experimental skin cancer vaccine, developed in collaboration with Merck & Co. The data showed that adding Moderna's intismeran autogene to Merck's KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits observed over the five-year period.Additionally, Bernstein raised its price target on Moderna to $35 from $25, reflecting increased confidence in the company's growth trajectory. This combination of promising clinical results and analyst optimism has fueled investor buying interest in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162010567","isCrawlerRequest":true}